Published in AIDS Weekly, October 2nd, 1995
Saquinavir, also known as Ro 31-8959 or Invirase, was the first of the new class of anti-HIV drugs known as protease inhibitors to reach advanced clinical trials. The arrival of protease inhibitors on the clinical scene has been eagerly awaited as they represent a new front in the war on AIDS: they attack a different point of the HIV replication cycle than currently approved drugs, which are all inhibitors of the HIV reverse transcriptase enzyme.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.